ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will post its quarterly earnings results before the market opens on Wednesday, November 1st. Analysts expect ANI Pharmaceuticals to post earnings of $0.99 per share for the quarter.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.20 million. During the same quarter in the previous year, the business earned $1.11 EPS. The company’s quarterly revenue was up 43.0% compared to the same quarter last year. On average, analysts expect ANI Pharmaceuticals to post $3.52 EPS for the current fiscal year and $4.21 EPS for the next fiscal year.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at 60.04 on Wednesday. The stock has a 50 day moving average price of $53.13 and a 200-day moving average price of $48.93. The company has a market cap of $698.75 million, a P/E ratio of 131.38 and a beta of 3.05. ANI Pharmaceuticals, Inc. has a 1-year low of $42.23 and a 1-year high of $67.10.

COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals, Inc. (ANIP) Scheduled to Post Earnings on Wednesday” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/25/ani-pharmaceuticals-inc-anip-scheduled-to-post-earnings-on-wednesday.html.

A number of research analysts have recently weighed in on ANIP shares. Guggenheim reissued a “buy” rating and issued a $80.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Canaccord Genuity started coverage on ANI Pharmaceuticals in a research note on Monday, July 31st. They issued a “buy” rating and a $60.00 price target on the stock. Finally, BidaskClub downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. ANI Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $67.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.